Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253918 | 0.81 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL681786 | 0.79 | NQO2 (0.50) | CCR1RAB9ACCR5KMT2AOPRK1 | |
| SCHEMBL1966328 | 0.78 | CCR1 (0.44) | CCR1RAB9ACCR5KMT2AOPRK1 | |
| SCHEMBL3462635 | 0.77 | HIPK2 (0.37) | RAB9ALMNAPDE4B | |
| SCHEMBL24810080 | 0.76 | HASPIN (0.33) | — | |
| SCHEMBL7362134 | 0.76 | KDM4E (0.32) | KMT2AKDM4ELMNAHTTMEN1 | |
| SCHEMBL30862165 | 0.76 | HASPIN (0.33) | — | |
| SCHEMBL15180209 | 0.76 | KMT2A (0.47) | KMT2AKDM4ELMNAHTTMEN1 | |
| SCHEMBL29862928 | 0.76 | KMT2A (0.47) | KMT2AKDM4ELMNAHTTMEN1 | |
| SCHEMBL28403258 | 0.75 | CA12 (0.36) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470208-B2 | Organometallic complexes | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-25 | — | — | US | disclosed |
| EP-1979437-B1 | ORGANOMETALLIC COMPLEXES | DU PONT (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20100264380-A1 | Organometallic complexes | E. I. DU PONT DE NEMOURS AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| EP-1979437-A2 | ORGANOMETALLIC COMPLEXES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-0952832-B1 | QUINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | DARWIN DISCOVERY LTD (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007087223-A2 | ORGANOMETALLIC COMPLEXES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
| US-6642254-B2 | Administering compounds, e.g., 8-methoxy-2-trifluoromethylquinoline-5-carboxylic acid (3,5-dichloro-1-oxypyridin-4-yl)amide for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase | DARWIN DISCOVERY, LTD. (GB) | 2003-11-04 | — | — | US | disclosed |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-12-05 | — | — | US | disclosed |
| US-6410559-B2 | 3,5-DISUBSTITUTED-(OXYPYRIDINE-4-YL)AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITOR TO TREAT INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE | DARWIN DISCOVERY, LTD. (GB) | 2002-06-25 | — | — | US | disclosed |
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2001-09-27 | — | — | US | disclosed |
| US-6262070-B1 | E.G., 8-METHOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYLIC ACID(3,5-DICHLORO-1-OXYPYRIDIN-4-YL)AMIDE; TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE | DARWIN DISCOVERY LTD. (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1045845-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | Darwin Discovery Limited (GB) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000026208-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
| US-5804588-A | TREATING DISEASES THAT ARE MODULATED BY INHIBITION OF PHOSPHODIESTERASE IV OR TUMOUR NECROSIS FACTOR | CHIROSCIENCE LIMITED (GB) | 1998-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | CBR1, CBR3, CYC1 | CCR1 27/4885RAB9A 1780/4885CCR5 385/4885 |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | CBR1, CBR3, CYC1 | CCR1 27/4885RAB9A 1780/4885CCR5 385/4885 |
| US-20100264380-A1 | Organometallic complexes | GSTO1, CYP4F12, CYP4F3 | CCR1 4212/4885RAB9A 2712/4885CCR5 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.